REG3A and Insulin resistance: Based on the results obtained in mice and in silico, and from a clinical perspective, this study suggests that the administration of a recombinant human REG3A protein may be a valuable approach to reduce peripheral insulin resistance and its associated comorbidities in overweight and type 2 diabetic patients.